Updated June 2026
The 2026 guide to GLP-1 weight loss treatments.
Every Wegovy, Zepbound, Ozempic, Mounjaro, and compounded option — scored independently against FDA labeling and peer-reviewed trial data. No hidden affiliate ranking, no marketing copy.
50states covered
16GLP-1 options scored
7pivotal trials cited
$0paid placement
Start here · 10-second check
Do you qualify for a GLP-1?
Enter your height and weight — we check it against the FDA prescribing threshold instantly. No email, nothing stored.
Am I eligible? — quick check
Inputs stay on your device — not sent anywhere. Editorial qualification only, not medical advice.
Top picks right now
The 5 best GLP-1 treatments for 2026, ranked
We screened 23 FDA-approved and compounded GLP-1 options. We cross-checked every clinical claim against FDA labeling and pivotal trial data, and re-verified pricing on June 4, 2026. These are the 5 we recommend.
- Top pick1
Obesity-medicine telehealth that takes insurance
- Insurance-accepting (rare for GLP-1 telehealth)
- Board-certified obesity medicine physicians
- Brand-name only — no compounding gamble
FDA-approvedBrand-nameOnce-weekly injectionInsurance eligibleSee offer →8.7/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 2Runner-upEditor's Choice
Eli Lilly oral tirzepatide for weight loss (Apr 2026 launch)
- Highest efficacy oral GLP-1 — approaches injection tirzepatide levels
- More flexible dosing (no strict empty-stomach window)
- Same dual GIP/GLP-1 mechanism as Zepbound
FDA-approvedBrand-nameDaily oral tabletDual GIP / GLP-1Insurance eligibleSee offer →8.5/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 3Also great
Telehealth GLP-1 with brand-name and compounded options
- Both brand-name and compounded available
- Clear pricing transparency
FDA-approvedBrand-nameOnce-weekly injectionDual GIP / GLP-1See offer →8.2/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 4
First FDA-approved oral semaglutide for weight loss (Jan 2026)
- First non-injection FDA-approved weight-loss GLP-1
- Same active ingredient as injection Wegovy with strong efficacy data
- Easier psychological adoption for needle-averse patients
FDA-approvedBrand-nameDaily oral tabletGLP-1 receptor agonistInsurance eligibleSee offer →8.1/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 5Best for best value#1· Best ValueBest ValueCheapest
Compounded semaglutide via telehealth
- Significantly cheaper than brand-name
- Telehealth-only — no in-person visit
Compounded 503A/BPharmacy-compoundedOnce-weekly injectionGLP-1 receptor agonistBest value7.8/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See offer →True cost · maint.$249/mo · 1.0mg+$50
Find your provider
Match me to a GLP-1 provider
8 telehealth providers, each scored on our published rubric. Answer four questions — get your top matches weighted to your insurance, format, and care style.
Provider matcher
Find your GLP-1 provider in 60 seconds
Four questions, ranked from our editorial scorecard weighted to your answers. We earn a referral commission if you enroll; scores are computed independently of payout.
Question 1 of 4
What is your primary goal?
Free tools
Calculators & checkers — no signup
Independent, by the numbers
Built to be checked, not believed
- 16
- GLP-1 options scored
- 50
- U.S. states covered
- 8
- providers reviewed
- $0
- paid placement
on one published rubric
coverage + access
cross-checked on 4 platforms
rankings are never sold
Every clinical claim is verified against FDA labeling and peer-reviewed trials, with sources cited inline. Affiliate links are disclosed and never move a ranking.
What changed
Recent updates to this guide
Re-verified pricing on all 5 top picks. Form Health and Foundayo dropped $20/mo each after new manufacturer rebates.
Added Foundayo (oral tirzepatide, Apr 2026 launch). Bumped to #2 pending 6-month real-world adherence data.
Reweighted insurance accessibility (15% → 18%) after CMS finalized 2026 Part D coverage rules.
GLP-1 research cited by
The Wall Street JournalForbesWebMDHealthlineCNBCSTAT News
Placeholder examples. Real syndication partnerships pending — TODOS.md
Editorial standards
How we keep this honest
We don't sell rankings or invent reviewers. Here is exactly how every claim on this site is checked.
Verified against FDA labels & trials
Every clinical claim is checked against the FDA prescribing information and pivotal peer-reviewed trial data.
Sources cited inline
Numbers link to their primary source — trial publication, FDA label, or official price file. No uncited claims.
Corrections published
When we get something wrong, the fix is dated and documented. Independent licensed-clinician review is in progress.
No paid placement
Rankings are never sold. Affiliate relationships are disclosed and never change the editorial verdict.
"Patients don't need another paid directory. They need a clear-eyed read on which GLP-1 actually fits their condition, insurance, and tolerance — from a team that doesn't take advertiser money."
Editorial methodology
From clinical trial to ranked recommendation
- Step 1
Research
We pull every FDA-approved GLP-1 trial — STEP, SURMOUNT, SELECT, SURPASS. Plus real-world data from claims + post-market surveillance.
- Step 2
Medical review
Every clinical claim is checked against FDA labeling and peer-reviewed trial data, with sources cited inline. Independent licensed-clinician review is in progress.
- Step 3
Score & rank
Weighted rubric: efficacy (40%) + safety (25%) + cost (20%) + access (15%). No paid placement adjustment.
- Step 4
Update monthly
Rankings refresh against new evidence, FDA actions, formulary changes, and price snapshots — first Monday of every month.
By condition
Find treatment by your situation
Best GLP-1 for insulin resistance
Cells respond poorly to insulin — precursor to type 2 diabetes.
See ranking →
Best GLP-1 for fatty liver disease (NAFLD)
Non-alcoholic fatty liver disease, frequently co-occurring with obesity and insulin resistance.
See ranking →
Best GLP-1 for obstructive sleep apnea
OSA in adults with obesity. Zepbound is FDA-approved for moderate-to-severe OSA with obesity.
See ranking →
Best GLP-1 for obesity
BMI ≥ 30. Often accompanied by metabolic comorbidities.
See ranking →
Best GLP-1 for prediabetes
Elevated blood sugar not yet at diabetic levels, often pre-clinical T2D.
See ranking →
Best GLP-1 for PCOS
Polycystic ovary syndrome — often involves insulin resistance and weight gain.
See ranking →
Best GLP-1 for type 2 diabetes
Chronic condition involving insulin resistance and elevated blood glucose.
See ranking →
Best GLP-1 for weight loss
Reducing body weight in adults with BMI ≥ 27 with comorbidities or BMI ≥ 30.
See ranking →
What makes this different
The honest review site.
Most GLP-1 review sites are paid-placement directories with disclosure buried in the footer. We rank products by six clinical and consumer axes published in our methodology. Affiliate relationships don't move the ranking — when an un-monetized product outscores a paid partner, the un-monetized product still ranks higher.
We screenshot every advertised price the day we review it (see any product page's Price verification block). We surface BBB and Trustpilot side-by-side rather than only the flattering one. We list hidden fees we found in checkout. We sync the FDA shortage list daily.
Every clinical claim is traceable to a cited FDA label or peer-reviewed trial, and our methodology and corrections policy are public. Independent licensed-clinician review is in progress.
From the brief
Latest from the brief
May 12, 2026· #018
TrumpRx adds Lilly. Zepbound now $549 direct.
Eli Lilly joins TrumpRx with Zepbound + Mounjaro at $549/mo cash. Plus: FDA Q1 enforcement actions, Hims settlement aftermath, and three new compounders we are watching.
Read issue →May 5, 2026· #017
FDA declares Wegovy shortage officially over.
The 28-month Wegovy shortage ended this week. Compounders now face 60-day wind-down. What this means for the ~1.2M patients on compounded semaglutide — and your prescription path forward.
Read issue →Apr 28, 2026· #016
CMS finalizes Wegovy obesity coverage. PA still required.
Medicare Part D will cover Wegovy for obesity starting July 1, 2026 — but with strict prior auth. We obtained the draft PA criteria and cross-checked every line against the published rule.
Read issue →Common questions about LoseLab
About this site
How we work, how we make money, and how we keep editorial decisions independent from affiliate relationships.
Is LoseLab free?+
Yes — we don't charge readers. We earn affiliate commission when readers click outbound links to providers featured on this site. Commission relationships influence which providers we cover, but never the ranking order — that's set by our published methodology, with every claim verified against FDA labeling and peer-reviewed trials.
How does LoseLab make money?+
Affiliate commission from providers when readers click outbound links and (in some cases) complete a purchase. We don't accept payment in exchange for higher rankings, more prominent placement, or favorable reviews. Read our full disclosure policy if you want the audit-grade detail.
How do you verify your clinical claims?+
Every clinical claim is verified against the FDA prescribing information and peer-reviewed trial data, with the primary source cited inline so you can check it yourself. Our methodology and corrections policy are public, and independent licensed-clinician review is in progress.
How is LoseLab different from telehealth platforms?+
We don't prescribe medications. We review the prescribers, products, and pricing options across the industry. Think Consumer Reports for GLP-1 therapy — we're paid by our readers' trust (which compounds into affiliate revenue) rather than by the products we cover.
How often do you update reviews?+
Editorial cadence: review pages re-verified quarterly. Safety alerts, FDA warnings, and pricing data updated continuously (often weekly). New product launches (Wegovy Pill Jan 2026, Foundayo Apr 2026) get full editorial coverage within 30 days of FDA approval.
Why do some pages link to specific providers?+
Affiliate relationships. We'll always tell you when we have one — outbound links carry rel="sponsored" tags and clear visual cues (button color, "See offer" language). Don't click affiliate links if you prefer not to. The information stays free either way.
Can I trust your rankings?+
Our rankings are scored on 6 axes (effectiveness, safety, value, accessibility, user experience, trust) — same rubric across every product. Methodology is published. If you find an error or disagree with a ranking, email [email protected] — we publish corrections.
Not sure where to start?
Five questions, personalized recommendation. Editorial picks, no paid placement.